

# Nigel S Key

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6668837/nigel-s-key-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

201  
papers

7,496  
citations

44  
h-index

84  
g-index

219  
ext. papers

8,827  
ext. citations

5.7  
avg, IF

6.18  
L-index

#	Paper	IF	Citations
201	Guidelines for the management of hemophilia. <i>Haemophilia</i> , <b>2013</b> , 19, e1-47	3.3	1227
200	Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2007</b> , 27, 1687-93	9.4	458
199	Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. <i>Blood</i> , <b>2003</b> , 102, 2678-83	2.2	435
198	Definitions in hemophilia: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , <b>2014</b> , 12, 1935-9	15.4	354
197	Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors. <i>Thrombosis and Haemostasis</i> , <b>1998</b> , 80, 912-918	7	325
196	Whole Blood Tissue Factor Procoagulant Activity Is Elevated in Patients With Sickle Cell Disease. <i>Blood</i> , <b>1998</b> , 91, 4216-4223	2.2	220
195	Sickle cell trait and the risk of venous thromboembolism among blacks. <i>Blood</i> , <b>2007</b> , 110, 908-12	2.2	177
194	Coagulation factor concentrates: past, present, and future. <i>Lancet, The</i> , <b>2007</b> , 370, 439-48	40	152
193	Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. <i>Blood</i> , <b>2012</b> , 119, 5543-52	2.2	148
192	Homogeneous low-molecular-weight heparins with reversible anticoagulant activity. <i>Nature Chemical Biology</i> , <b>2014</b> , 10, 248-50	11.7	147
191	Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. <i>Lancet Haematology, the</i> , <b>2019</b> , 6, e295-e305	14.6	144
190	Hypercoagulability in sickle cell disease: new approaches to an old problem. <i>Hematology American Society of Hematology Education Program</i> , <b>2007</b> , 2007, 91-6	3.1	134
189	Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 2115-25	27.4	126
188	In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps. <i>Blood</i> , <b>2017</b> , 129, 1021-1029	2.2	123
187	Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: studies using a new digital flow cytometer. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , <b>2007</b> , 71, 38-45	4.6	109
186	Inhibitors in congenital coagulation disorders. <i>British Journal of Haematology</i> , <b>2004</b> , 127, 379-91	4.5	106
185	Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. <i>Journal of Thrombosis and Haemostasis</i> , <b>2016</b> , 14, 153-66	15.4	93

184	Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. <i>Blood</i> , <b>2014</b> , 123, 1747-56	2.2	84
183	Tissue factor and its measurement in whole blood, plasma, and microparticles. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2010</b> , 36, 865-75	5.3	81
182	Microparticle analysis in disorders of hemostasis and thrombosis. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , <b>2016</b> , 89, 111-22	4.6	79
181	Association of coagulation activation with clinical complications in sickle cell disease. <i>PLoS ONE</i> , <b>2012</b> , 7, e29786	3.7	78
180	Coagulation Abnormalities and Thrombosis in Patients Infected With SARS-CoV-2 and Other Pandemic Viruses. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2020</b> , 40, 2033-2044	9.4	78
179	Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies. <i>Blood Reviews</i> , <b>2016</b> , 30, 245-56	11.1	77
178	Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. <i>Blood</i> , <b>2012</b> , 120, 636-46	2.2	76
177	Standardization of microparticle enumeration across different flow cytometry platforms: results of a multicenter collaborative workshop. <i>Journal of Thrombosis and Haemostasis</i> , <b>2017</b> , 15, 187-193	15.4	73
176	Prospective study of sickle cell trait and venous thromboembolism incidence. <i>Journal of Thrombosis and Haemostasis</i> , <b>2015</b> , 13, 2-9	15.4	72
175	Sickle-cell trait: novel clinical significance. <i>Hematology American Society of Hematology Education Program</i> , <b>2010</b> , 2010, 418-22	3.1	72
174	Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. <i>Thrombosis and Haemostasis</i> , <b>1998</b> , 80, 912-8	7	70
173	Neutrophils: back in the thrombosis spotlight. <i>Blood</i> , <b>2019</b> , 133, 2186-2197	2.2	66
172	Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. <i>Blood</i> , <b>1998</b> , 91, 4216-23	2.2	64
171	High prevalence of sickle cell trait in African Americans with ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2010</b> , 21, 413-7	12.7	61
170	Synthetic oligosaccharides can replace animal-sourced low-molecular weight heparins. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	60
169	Elevated hematocrit enhances platelet accumulation following vascular injury. <i>Blood</i> , <b>2017</b> , 129, 2537-2546		59
168	Excess of heme induces tissue factor-dependent activation of coagulation in mice. <i>Haematologica</i> , <b>2015</b> , 100, 308-14	6.6	58
167	Epidemiologic and clinical data linking factors XI and XII to thrombosis. <i>Hematology American Society of Hematology Education Program</i> , <b>2014</b> , 2014, 66-70	3.1	58

166	Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors. <i>Haematologica</i> , <b>2020</b> , 105, 218-225	6.6	57
165	Hyperhomocyst(e)inemia and Thrombophilia. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2002</b> , 126, 1367-75	5	55
164	Measurement of microparticle tissue factor activity in clinical samples: A summary of two tissue factor-dependent FXa generation assays. <i>Thrombosis Research</i> , <b>2016</b> , 139, 90-7	8.2	54
163	How I treat patients with inherited bleeding disorders who need anticoagulant therapy. <i>Blood</i> , <b>2016</b> , 128, 178-84	2.2	51
162	Analysis of tissue factor positive microparticles. <i>Thrombosis Research</i> , <b>2010</b> , 125 Suppl 1, S42-5	8.2	50
161	Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. <i>Haemophilia</i> , <b>2012</b> , 18, 798-804	3.3	48
160	Using heparin molecules to manage COVID-2019. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2020</b> , 4, 518-523	5.1	47
159	Sickle cell trait and incident ischemic stroke in the Atherosclerosis Risk in Communities study. <i>Stroke</i> , <b>2014</b> , 45, 2863-7	6.7	46
158	Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women. <i>American Journal of Obstetrics and Gynecology</i> , <b>2009</b> , 200, 620.e1-3	6.4	44
157	Global assays of fibrinolysis. <i>International Journal of Laboratory Hematology</i> , <b>2017</b> , 39, 441-447	2.5	42
156	Microparticles in sickle cell anaemia: promise and pitfalls. <i>British Journal of Haematology</i> , <b>2016</b> , 174, 16-20	5	40
155	NHF-McMaster Guideline on Care Models for Haemophilia Management. <i>Haemophilia</i> , <b>2016</b> , 22 Suppl 3, 6-16	3.3	40
154	Thrombin generation and cell-dependent hypercoagulability in sickle cell disease. <i>Journal of Thrombosis and Haemostasis</i> , <b>2016</b> , 14, 1941-1952	15.4	38
153	Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. <i>Blood Advances</i> , <b>2019</b> , 3, 3241-3247	7.8	37
152	The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 359-371	8.7	36
151	Negative health implications of sickle cell trait in high income countries: from the football field to the laboratory. <i>British Journal of Haematology</i> , <b>2015</b> , 170, 5-14	4.5	36
150	Platelets and platelet-derived factor Va confer hemostatic competence in complete factor V deficiency. <i>Blood</i> , <b>2015</b> , 125, 3647-50	2.2	32
149	Procoagulant microparticles promote coagulation in a factor XI-dependent manner in human endotoxemia. <i>Journal of Thrombosis and Haemostasis</i> , <b>2016</b> , 14, 1031-42	15.4	32

148	Contact System Activation and Cancer: New Insights in the Pathophysiology of Cancer-Associated Thrombosis. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, 251-265	7	31
147	How to discuss gene therapy for haemophilia? A patient and physician perspective. <i>Haemophilia</i> , <b>2019</b> , 25, 545-557	3.3	29
146	Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways. <i>Blood</i> , <b>2020</b> , 135, 755-765	2.2	26
145	Membrane microparticles in VTE and cancer. <i>Thrombosis Research</i> , <b>2010</b> , 125 Suppl 2, S80-3	8.2	25
144	Views on methods for monitoring recombinant factor VIIa in inhibitor patients. <i>Seminars in Hematology</i> , <b>2004</b> , 41, 51-4	4	25
143	Hemolytic anemia in protoporphyria: possible precipitating role of liver failure and photic stress. <i>American Journal of Hematology</i> , <b>1992</b> , 39, 202-7	7.1	25
142	Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis. <i>Haematologica</i> , <b>2019</b> , 104, 653-658	6.6	24
141	Red Blood Cell Adhesion to Heme-Activated Endothelial Cells Reflects Clinical Phenotype in Sickle Cell Disease. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 1050	7.1	24
140	Analysis of anticoagulation strategies for venous thromboembolism during severe thrombocytopenia in patients with hematologic malignancies: a retrospective cohort. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 2573-2581	1.9	23
139	Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease. <i>Blood</i> , <b>2019</b> , 133, 2529-2541	2.2	23
138	Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. <i>Cancer Research</i> , <b>2016</b> , 76, 3671-5	10.1	23
137	Plasma microparticle tissue factor activity in patients with antiphospholipid antibodies with and without clinical complications. <i>Thrombosis Research</i> , <b>2014</b> , 133, 187-9	8.2	23
136	Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report. <i>HemaSphere</i> , <b>2019</b> , 3, e286	0.3	23
135	Measuring circulating cell-derived microparticles. <i>Journal of Thrombosis and Haemostasis</i> , <b>2004</b> , 2, 1848-1850	15.4	22
134	A cross-sectional analysis of cardiovascular disease in the hemophilia population. <i>Blood Advances</i> , <b>2018</b> , 2, 1325-1333	7.8	22
133	Sickle Cell Trait Worsens Oxidative Stress, Abnormal Blood Rheology, and Vascular Dysfunction in Type 2 Diabetes. <i>Diabetes Care</i> , <b>2015</b> , 38, 2120-7	14.6	21
132	Design of anti-inflammatory heparan sulfate to protect against acetaminophen-induced acute liver failure. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	20
131	Thrombin activation of PAR-1 contributes to microvascular stasis in mouse models of sickle cell disease. <i>Blood</i> , <b>2020</b> , 135, 1783-1787	2.2	19

130	Coagulation activation in sickle cell trait: an exploratory study. <i>British Journal of Haematology</i> , <b>2015</b> , 171, 638-46	4.5	19
129	Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 42-9	7	19
128	Impact of sickle hemoglobinopathies on pregnancy-related venous thromboembolism. <i>American Journal of Perinatology</i> , <b>2014</b> , 31, 805-9	3.3	18
127	Potent irreversible P2Y12 inhibition does not reduce LPS-induced coagulation activation in a randomized, double-blind, placebo-controlled trial. <i>Clinical Science</i> , <b>2016</b> , 130, 433-40	6.5	18
126	Impact of an innovative blood factor stewardship program on drug expense and patient care. <i>American Journal of Health-System Pharmacy</i> , <b>2015</b> , 72, 1579-84	2.2	17
125	Current treatment of venous thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2010</b> , 30, 372-5	9.4	17
124	Prevalence of inherited blood disorders and associations with malaria and anemia in Malawian children. <i>Blood Advances</i> , <b>2018</b> , 2, 3035-3044	7.8	17
123	Thrombin-independent contribution of tissue factor to inflammation and cardiac hypertrophy in a mouse model of sickle cell disease. <i>Blood</i> , <b>2016</b> , 127, 1371-3	2.2	15
122	Care models in the management of haemophilia: a systematic review. <i>Haemophilia</i> , <b>2016</b> , 22 Suppl 3, 31-40	3.3	14
121	Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors. <i>Haemophilia</i> , <b>2017</b> , 23, 33-41	3.3	14
120	Microparticles in sickle cell disease. <i>Clinical Hemorheology and Microcirculation</i> , <b>2018</b> , 68, 319-329	2.5	13
119	Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. <i>Blood Advances</i> , <b>2021</b> , 5, 1682-1694	7.8	13
118	Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products. <i>Blood Advances</i> , <b>2019</b> , 3, 1429-1440	7.8	13
117	Tissue factor; from Morawitz to microparticles. <i>Transactions of the American Clinical and Climatological Association</i> , <b>2007</b> , 118, 165-73	0.9	12
116	Establishing sickle cell diagnostics and characterizing a paediatric sickle cell disease cohort in Malawi. <i>British Journal of Haematology</i> , <b>2016</b> , 174, 325-9	4.5	11
115	Perioperative management of rare coagulation factor deficiency states in cardiac surgery. <i>British Journal of Anaesthesia</i> , <b>2017</b> , 119, 354-368	5.4	11
114	Sickle cell disease and venous thromboembolism in pregnancy and the puerperium. <i>Thrombosis Research</i> , <b>2015</b> , 135 Suppl 1, S46-8	8.2	11
113	Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial. <i>Blood</i> , <b>2020</b> , 136, 1-2	2.2	11

112	Red blood cell adhesion to ICAM-1 is mediated by fibrinogen and is associated with right-to-left shunts in sickle cell disease. <i>Blood Advances</i> , <b>2020</b> , 4, 3688-3698	7.8	11
111	Platelet tissue factor: how did it get there and is it important?. <i>Seminars in Hematology</i> , <b>2008</b> , 45, S16-204		10
110	Quantification of citrullinated histones: Development of an improved assay to reliably quantify nucleosomal H3Cit in human plasma. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2732-2743	15.4	10
109	Protocol adherence when managing massive bleeding following complex cardiac surgery: a study design pilot. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , <b>2015</b> , 29, 303-10	2.1	9
108	Development and application of global assays of hyper- and hypofibrinolysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2020</b> , 4, 46-53	5.1	9
107	Sickle cell trait is not associated with an increased risk of heart failure or abnormalities of cardiac structure and function. <i>Blood</i> , <b>2017</b> , 129, 799-801	2.2	8
106	Lower doses of recombinant porcine factor VIII maintain excellent haemostatic efficacy. <i>Haemophilia</i> , <b>2016</b> , 22, e549-e551	3.3	8
105	Red blood cells and thrombin generation in sickle cell disease. <i>Thrombosis Research</i> , <b>2014</b> , 133 Suppl 1, S52-3	8.2	8
104	Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients. <i>Kidney International</i> , <b>2011</b> , 80, 992-999	9.9	8
103	Excessive breakthrough bleeding in haemophilia B patients on factor IX-albumin fusion protein prophylactic therapy: A single centre case series. <i>Haemophilia</i> , <b>2020</b> , 26, e23-e25	3.3	8
102	Variability in Institutional Guidance for COVID-19-Associated Coagulopathy in the United States. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 1725-1732	7	8
101	Global assays of fibrinolysis. <i>International Journal of Laboratory Hematology</i> , <b>2017</b> , 39, e142-e143	2.5	7
100	Thirty-year risk of ischemic stroke in individuals with sickle cell trait and modification by chronic kidney disease: The atherosclerosis risk in communities (ARIC) study. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 1306-1313	7.1	7
99	Coagulation inhibition for sepsis. <i>Current Opinion in Hematology</i> , <b>2002</b> , 9, 416-21	3.3	7
98	Hemoglobin levels and coronary heart disease risk by age, race, and sex in the reasons for geographic and racial differences in stroke study (REGARDS). <i>American Journal of Hematology</i> , <b>2020</b> , 95, 258-266	7.1	7
97	Nephrin as a biomarker of sickle cell glomerulopathy in Malawi. <i>Pediatric Blood and Cancer</i> , <b>2018</b> , 65, e26993	3	6
96	Joint WFH-ISTH session: issues in clinical trial design. <i>Haemophilia</i> , <b>2014</b> , 20 Suppl 4, 137-44	3.3	6
95	Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference. <i>Journal of Trauma and Acute Care Surgery</i> , <b>2021</b> , 91, S18-S25	3.3	6

94	In vitro and in vivo characterization of a reversible synthetic heparin analog. <i>Thrombosis Research</i> , <b>2016</b> , 138, 121-129	8.2	5
93	Bench to bedside: new developments in our understanding of the pathophysiology of thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2013</b> , 35, 342-5	5.1	5
92	Whole Blood Tissue Factor Procoagulant Activity Is Elevated in Patients With Sickle Cell Disease. <i>Blood</i> , <b>1998</b> , 91, 4216-4223	2.2	5
91	D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer. <i>Oncologist</i> , <b>2020</b> , 25, 1075-1083	5.7	5
90	Initial strides for invent-VTE: Towards global collaboration to accelerate clinical research in venous thromboembolism. <i>Thrombosis Research</i> , <b>2018</b> , 163, 128-131	8.2	4
89	Protective and detrimental effects of neuroectodermal cell-derived tissue factor in mouse models of stroke. <i>JCI Insight</i> , <b>2016</b> , 1,	9.9	4
88	Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohort. <i>Blood Advances</i> , <b>2020</b> , 4, 6240-6249	7.8	4
87	Plasmin-mediated cleavage of high-molecular-weight kininogen contributes to acetaminophen-induced acute liver failure. <i>Blood</i> , <b>2021</b> , 138, 259-272	2.2	4
86	Genetic basis of ethnic disparities in VTE risk. <i>Blood</i> , <b>2016</b> , 127, 1844-5	2.2	4
85	Current insights on the risk of thrombogenicity with off-label use of rFVIIa. <i>Clinical Advances in Hematology and Oncology</i> , <b>2006</b> , 4, 34-5	0.6	4
84	High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2329-2340	15.4	3
83	Pregnancy in sickle cell trait: what we do and don't know. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 328-335	7.3	3
82	Effect of eptifibatid on inflammation during acute pain episodes in sickle cell disease. <i>American Journal of Hematology</i> , <b>2018</b> , 93, E99-E101	7.1	3
81	Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2018</b> , 2, 407-428	5.1	3
80	Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study. <i>Thrombosis Research</i> , <b>2020</b> , 191 Suppl 1, S31-S36	8.2	3
79	Emicizumab reduces re-hospitalization for bleeding in acquired haemophilia A. <i>Haemophilia</i> , <b>2021</b> , 27, e585-e588	3.3	3
78	Association of Sickle Cell Trait With Incidence of Coronary Heart Disease Among African American Individuals. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2030435	10.4	3
77	Tissue factor as a therapeutic target. <i>Thrombosis and Haemostasis</i> , <b>2001</b> , 85, 375-6	7	3



76	Management of adult non-severe haemophilia A patients with inhibitors: a practice-pattern survey. <i>Haemophilia</i> , <b>2015</b> , 21, e422-4	3.3	2
75	Association of sickle cell trait with measures of cognitive function and dementia in African Americans. <i>ENeurologicalSci</i> , <b>2019</b> , 16, 100201	2.1	2
74	Thrombotic Thrombocytopenic Purpura associated with Pembrolizumab.. <i>Journal of Oncology Pharmacy Practice</i> , <b>2022</b> , 10781552211073883	1.7	2
73	Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study.. <i>Journal of Thrombosis and Haemostasis</i> , <b>2022</b> ,	15.4	2
72	All-Cause and Inhibitor-Related Mortality in Non-Severe Hemophilia [Patients in the United States. <i>Blood</i> , <b>2019</b> , 134, 902-902	2.2	2
71	Administration of FFP Repletes and Sustains the Megakaryocyte/Platelet-Derived Factor V Pool To Confer Hemostatic Competence in a Factor V-Deficient Individual.. <i>Blood</i> , <b>2005</b> , 106, 1779-1779	2.2	2
70	Treatment of Venous Thromboembolism in Patients with Hematological Malignancies and Severe Thrombocytopenia: A Retrospective Cohort Analysis. <i>Blood</i> , <b>2016</b> , 128, 531-531	2.2	2
69	Adhesion of Sickle RBCs to Heme-Activated Endothelial Cells Correlates with Patient Clinical Phenotypes. <i>Blood</i> , <b>2017</b> , 130, 959-959	2.2	2
68	Alteration of the Structure and Dynamics of Venous Clot Formation in Human and Murine Sickle Cell Disease. <i>Blood</i> , <b>2016</b> , 128, 2478-2478	2.2	2
67	Management of inhibitors in persons with non-severe hemophilia A in the United States. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E9-E11	7.1	2
66	Neutrophil Extracellular Trap Formation and Syndecan-1 Shedding Are Increased After Trauma. <i>Shock</i> , <b>2021</b> , 56, 433-439	3.4	2
65	Tranexamic acid rapidly inhibits fibrinolysis, yet transiently enhances plasmin generation in vivo. <i>Blood Coagulation and Fibrinolysis</i> , <b>2021</b> , 32, 172-179	1	2
64	Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. <i>Haemophilia</i> , <b>2021</b> , 27, 211-220	3.3	2
63	DDAVP trial in discrepant non-severe haemophilia A patients. <i>Haemophilia</i> , <b>2018</b> , 24, e152-e154	3.3	1
62	Vascular haemostasis. <i>Haemophilia</i> , <b>2010</b> , 16 Suppl 5, 146-51	3.3	1
61	Diagnostic approaches to bleeding disorders. <i>Hematology</i> , <b>2005</b> , 10 Suppl 1, 29-32	2.2	1
60	Upregulation of Tissue Factor May Contribute to Thrombosis in Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , <b>2018</b> , 132, 2513-2513	2.2	1
59	Rituximab Monotherapy Is Effective for Inhibitor Eradication with Concomitant Porcine Factor VIII Followed By Emicizumab for Bleed Control in Acquired Hemophilia a. <i>Blood</i> , <b>2021</b> , 138, 348-348	2.2	1

58	Pathologically stiff erythrocytes impede contraction of blood clots: Comment. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 2893-2894	15.4	1
57	Sickle Cell Trait, Oral Contraceptives, and the Risk of Venous Thromboembolism.. <i>Blood</i> , <b>2007</b> , 110, 1627-1627	1	1
56	Histones Induce the Release of Extracellular Hemoglobin and Red Blood Cell-Derived Microvesicles with Procoagulant Activity. <i>Blood</i> , <b>2018</b> , 132, 2514-2514	2.2	1
55	Recombinant Porcine Factor VIII Use in Bleed Treatment in Non-Severe Hemophilia a Inhibitor Patients: Dosing Strategies and Efficacy. <i>Blood</i> , <b>2018</b> , 132, 1202-1202	2.2	1
54	Type-2 Phosphatidylserine (PS)-Positive Erythrocytes and Their Association with Markers of Hemolysis and Hemostatic Activation in Children with Sickle Cell Disease (SCD). <i>Blood</i> , <b>2015</b> , 126, 943-943	2.2	1
53	Inhibitors and mortality in persons with nonsevere hemophilia A in the United States. <i>Blood Advances</i> , <b>2020</b> , 4, 4739-4747	7.8	1
52	Protease: Serpin complexes to assess contact system and intrinsic pathway activation. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2020</b> , 4, 789-798	5.1	1
51	Hemodialysis-Related Complement and Contact Pathway Activation and Cardiovascular Risk: A Narrative Review. <i>Kidney Medicine</i> , <b>2021</b> , 3, 607-618	2.8	1
50	Cardiothoracic Surgery <b>2016</b> , 299-313		1
49	Molecular Diagnostic Approaches to Hemostasis <b>2016</b> , 27-41		1
48	Hemophilia A and B <b>2016</b> , 79-93		1
47	OC-04 - Tissue factor positive microvesicles activate platelets in vitro and in vivo and enhance thrombosis in mice. <i>Thrombosis Research</i> , <b>2016</b> , 140 Suppl 1, S169-70	8.2	1
46	Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 201-216	15.4	1
45	Euglobulin clot lysis time reveals a high frequency of fibrinolytic activation in trauma. <i>Thrombosis Research</i> , <b>2021</b> , 204, 22-28	8.2	1
44	Prolonged Remission of Cancer of Unknown Primary following Initiation of Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria. <i>Case Reports in Hematology</i> , <b>2019</b> , 2019, 2587597	0.7	0
43	Tissue factor activity is increased in neutrophils from JAK2 V617F-mutated essential thrombocythemia and polycythemia vera patients. <i>American Journal of Hematology</i> , <b>2021</b> ,	7.1	0
42	Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model. <i>Haemophilia</i> , <b>2021</b> , 27, 974-983	3.3	0
41	Harold Ross Roberts, MD, 1930-2017. <i>Haemophilia</i> , <b>2018</b> , 24, 13-14	3.3	

40	Acquired Inhibitors of Coagulation <b>2016</b> , 124-133	
39	Von Willebrand Disease <b>2016</b> , 94-112	
38	New players in Trousseau syndrome. <i>Blood</i> , <b>2015</b> , 126, 1270-2	2.2
37	Cluster of inhibitors among adult inpatients with haemophilia in a single institution. <i>Haemophilia</i> , <b>2015</b> , 21, e325-8	3.3
36	Utility of Inferior Vena Cava Filter in the Management of Venous Thromboembolism Among Patients with Brain Metastases: A Population-Based Study. <i>Blood</i> , <b>2020</b> , 136, 47-48	2.2
35	Venous Thromboembolism Incidence and Impact on Survival in Patients with Brain Metastases. <i>Blood</i> , <b>2020</b> , 136, 1-1	2.2
34	Emizicumab Promotes Factor Xa Generation on Activated Endothelium in a Blood Cell-Independent Manner. <i>Blood</i> , <b>2021</b> , 138, 3182-3182	2.2
33	Phosphatidylserine-Positive Erythrocytes Modulate Tissue Factor Activity In Vivo and In Vitro in Sickle Cell Disease.. <i>Blood</i> , <b>2004</b> , 104, 240-240	2.2
32	Proteomics in the Study of Qualitative Platelet Defects: Validation of the Approach in the Gray Platelet Syndrome and Quebec Platelet Disorder.. <i>Blood</i> , <b>2007</b> , 110, 3900-3900	2.2
31	Glycosaminoglycans as Anticoagulants in Mucopolysaccharidosis Type I (MPS I).. <i>Blood</i> , <b>2007</b> , 110, 3951-3951	2.2
30	Glycosaminoglycans as Anticoagulants in Mucopolysaccharidosis Type I (MPS I).. <i>Blood</i> , <b>2007</b> , 110, 2160.5-2160.5	2.2
29	Enhanced VTE Risk Stratification in Ambulatory Patients with Cancer. <i>Blood</i> , <b>2019</b> , 134, 634-634	2.2
28	High Molecular Weight Kininogen but Not Factor XII Deficiency Attenuates Acetaminophen-Induced Liver Injury in Mice. <i>Blood</i> , <b>2019</b> , 134, 3621-3621	2.2
27	HemoglobinA2 Levels Associate with Lower ESA-Dose in African-Americans with Sickle Cell Trait and End-Stage Kidney Disease. <i>Blood</i> , <b>2015</b> , 126, 3407-3407	2.2
26	Purified DNA, but Not Neutrophil Extracellular Traps (NETs), Promotes Contact Activation of Coagulation. <i>Blood</i> , <b>2015</b> , 126, 767-767	2.2
25	Reference Ranges444-451	
24	Early Renal Disease in Children with Sickle Cell Disease from Malawi. <i>Blood</i> , <b>2016</b> , 128, 1316-1316	2.2
23	Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer. <i>Thrombosis Research</i> , <b>2020</b> , 196, 437-443	8.2

- 22 An exploratory study of the effects of strenuous exercise on markers of coagulation activation, circulating microparticles, and inflammation in sickle cell trait. *EJHaem*, **2020**, 1, 251-254 0.9
- 21 Basic Principles Underlying Coagulation **2016**, 1-11
- 20 Quantitative Platelet Disorders **2016**, 134-159
- 19 Qualitative Platelet Disorders **2016**, 160-171
- 18 Thrombotic Microangiopathies **2016**, 183-194
- 17 Myeloproliferative Neoplasms: Thrombosis and Hemorrhage **2016**, 210-228
- 16 Arterial Thrombosis **2016**, 229-239
- 15 Anticoagulation: Heparins and Vitamin K Antagonists **2016**, 240-252
- 14 The Direct Oral Anticoagulants **2016**, 253-268
- 13 Laboratory Tests of Hemostasis **2016**, 12-26
- 12 Cardiovascular Medicine **2016**, 282-298
- 11 Hepatology **2016**, 329-339
- 10 Obstetrics, Contraception, and Estrogen Replacement **2016**, 379-392
- 9 Intensive and Critical Care **2016**, 414-432
- 8 Transfusion **2016**, 433-443
- 7 Tests of Platelet Function **2016**, 42-62
- 6 Evaluation of the Bleeding Patient **2016**, 63-78
- 5 The Rarer Inherited Coagulation Disorders **2016**, 113-123

- 4 Corrigendum to "Measurement of microparticle tissue factor activity in clinical samples: A summary of two tissue factor-dependent FXa generation assays" [Thromb. Res. 139 (2016) 90-97]. *Thrombosis Research*, **2016**, 147, 63 8.2
- 3 Recombinant porcine factor VIII use in bleed treatment in non-severe haemophilia A inhibitor patients: Dosing strategies and efficacy. *Haemophilia*, **2021**, 27, e147-e150 3.3
- 2 A pilot study of the effect of rivaroxaban in sickle cell anemia. *Transfusion*, **2021**, 61, 1694-1698 2.9
- 1 Prevalence and outcomes of dehydration in adults with sickle cell trait: the Atherosclerosis Risk in Communities (ARIC) study.. *British Journal of Haematology*, **2022**, 4.5